Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335).
about
Combined X-ray, NMR, and Kinetic Analyses Reveal Uncommon Binding Characteristics of the Hepatitis C Virus NS3-NS4A Protease Inhibitor BI 201335Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.Identification of novel small molecules as inhibitors of hepatitis C virus by structure-based virtual screening.Current and future therapies for hepatitis C virus infection: from viral proteins to host targets.Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV.Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study.Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure.Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A proteaseMass balance and metabolite profiling of steady-state faldaprevir, a hepatitis C virus NS3/4 protease inhibitor, in healthy male subjects.In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.Advanced asymmetric synthesis of (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid by alkylation/cyclization of newly designed axially chiral Ni(II) complex of glycine Schiff base.Hepatitis C virus serine protease: synthesis of radioactive and stable isotope-labeled potent inhibitors.Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection.Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor.Proteases and protease inhibitors in infectious diseases.Biotransformation and mass balance of faldaprevir, a hepatitis C NS3/NS4 protease inhibitor in rats
P2860
Q27666747-F56E8E58-8FD6-4386-AEC9-4E6E586F05A7Q34396312-015763D8-CFE2-4501-92F9-09D6FE395306Q35050116-5308179D-6ECB-4BF7-A76A-F2A4A1CE549DQ38131681-3CEB81EB-2438-4CDF-979C-99CB810B1319Q38172277-094E8399-3F5A-468D-BDD2-BE96948EED09Q39121699-87957228-DA83-4AF5-9D33-00ED64F48CD9Q39507721-3670B96B-61B0-4FCA-9982-9B4E324C79DEQ39658512-C69956D8-822A-44CD-A024-DD2C02A8E107Q39682787-82E88E47-85E7-49FB-BAD9-C2A365BF4414Q40327697-C4EDDB85-ED6A-4C4B-AB61-1B48089D6107Q41055857-67AFD65E-879D-4E31-B88B-498254F38767Q42226897-9FD574DF-0245-4089-9007-D93A03E61E97Q42276777-0809BD81-EBCE-4DF7-97DA-C5DC16D6D515Q43041164-8CDD683B-FA03-46EF-8874-ADA0B44D6B46Q47576680-FC574B64-AD76-4DCB-BCC4-DA2EE8D98AEAQ57149258-B11EB754-8923-47D7-8489-190AB1DDC80E
P2860
Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335).
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Discovery of a potent and sele ...... irus NS3 protease (BI 201335).
@en
Discovery of a potent and sele ...... hepatitis C virus NS3 protease
@nl
type
label
Discovery of a potent and sele ...... irus NS3 protease (BI 201335).
@en
Discovery of a potent and sele ...... hepatitis C virus NS3 protease
@nl
prefLabel
Discovery of a potent and sele ...... irus NS3 protease (BI 201335).
@en
Discovery of a potent and sele ...... hepatitis C virus NS3 protease
@nl
P2093
P356
P1476
Discovery of a potent and sele ...... virus NS3 protease (BI 201335)
@en
P2093
Elise Ghiro
Jiamin Duan
Josée Bordeleau
Julie Naud
Marc-André Poupart
Michael Bös
Michael G Cordingley
Michel Garneau
Montse Llinàs-Brunet
Murray D Bailey
P304
P356
10.1021/JM100690X
P407
P50
P577
2010-09-01T00:00:00Z